Hikma Pharmaceuticals Plc (LON:HIK) declared a dividend on Friday, August 9th, Upcoming.Co.Uk reports. Stockholders of record on Thursday, August 22nd will be paid a dividend of $0.14 per share on Monday, September 23rd. This represents a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, August 22nd. The official announcement can be seen at this link.
Shares of LON:HIK opened at GBX 2,018 ($26.37) on Friday. Hikma Pharmaceuticals has a 1 year low of GBX 1,491.50 ($19.49) and a 1 year high of GBX 2,089 ($27.30). The stock’s fifty day moving average price is GBX 1,824.35 and its 200-day moving average price is GBX 1,735.26. The company has a debt-to-equity ratio of 37.69, a current ratio of 1.28 and a quick ratio of 0.78. The company has a market cap of $4.89 billion and a P/E ratio of 13.56.
HIK has been the topic of a number of recent research reports. JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 1,700 ($22.21) target price on shares of Hikma Pharmaceuticals in a report on Tuesday, June 18th. Barclays restated an “equal weight” rating and issued a GBX 1,800 ($23.52) price target on shares of Hikma Pharmaceuticals in a research report on Friday, May 3rd. Finally, Peel Hunt restated a “hold” rating and issued a GBX 2,050 ($26.79) price target (up previously from GBX 1,870 ($24.43)) on shares of Hikma Pharmaceuticals in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 1,834.29 ($23.97).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Further Reading: Why do companies issue convertible shares?
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.